Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double Blind, Placebo-Controlled Study to Evaluate the Effect of Nicotinamide Mononucleotide (NMN) As an Adjuvant to Standard of Care (SOC) On Fatigue Associated With COVID-19 Infection

NCT05175768 is registered in ClinicalTrials.gov with Vedic Lifesciences Pvt. Ltd. as lead sponsor.

NCT NCT05175768
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05175768 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double Blind, Placebo-Controlled Study to Evaluate the Effect of Nicotinamide Mononucleotide (NMN) As an Adjuvant to Standard of Care (SOC) On Fatigue Associated With COVID-19 Infection
Lead sponsor
Vedic Lifesciences Pvt. Ltd.
Phase
Not applicable
Overall status
Terminated
Start date
December 27, 2021
Completion date
July 16, 2022
Enrollment
69 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19 infection